HomeComparePSTI vs SPHD

PSTI vs SPHD: Dividend Comparison 2026

PSTI yields 200.00% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PSTI wins by $119.34M in total portfolio value
10 years
PSTI
PSTI
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full PSTI calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — PSTI vs SPHD

📍 PSTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPSTISPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PSTI + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PSTI pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PSTI
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, PSTI beats the other by $51,149,196.22/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PSTI + SPHD for your $10,000?

PSTI: 50%SPHD: 50%
100% SPHD50/50100% PSTI
Portfolio after 10yr
$59.70M
Annual income
$30,088,333.80/yr
Blended yield
50.40%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PSTI right now

PSTI
Analyst Ratings
8
Buy
2
Hold
Consensus: Buy
Altman Z
-41.5
Piotroski
4/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PSTI buys
0
SPHD buys
0
No recent congressional trades found for PSTI or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPSTISPHD
Forward yield200.00%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$119.36M$26.5K
Annual income after 10y$60,176,096.29$571.32
Total dividends collected$112.49M$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: PSTI vs SPHD ($10,000, DRIP)

YearPSTI PortfolioPSTI Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$30,700$20,000.00$11,133$432.85+$19.6KPSTI
2$90,232$57,383.18$12,363$450.36+$77.9KPSTI
3$254,173$157,624.56$13,695$467.39+$240.5KPSTI
4$686,927$414,961.74$15,138$483.90+$671.8KPSTI
5$1,783,118$1,048,106.39$16,697$499.88+$1.77MPSTI
6$4,450,613$2,542,677.12$18,382$515.31+$4.43MPSTI
7$10,693,420$5,931,263.38$20,198$530.17+$10.67MPSTI
8$24,760,608$13,318,648.86$22,157$544.46+$24.74MPSTI
9$55,315,649$28,821,798.66$24,266$558.18+$55.29MPSTI
10$119,363,841$60,176,096.29$26,536$571.32+$119.34MPSTI

PSTI vs SPHD: Complete Analysis 2026

PSTIStock

Pluristem Therapeutics Inc. operates as a bio-technology company. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trial for the recovery after surgery for hip fracture; in Phase II clinical trail for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18, which has completed Phase I clinical trial incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of acute radiation syndrome. The company has a license agreement for conducting clinical trials of PLX-PAD product in South Korea. It also has a collaborative project nTRACK, that examines gold nano particles labeling of stem cells; and has collaboration agreement with the NASA's Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was incorporated in 2001 and is based in Haifa, Israel.

Full PSTI Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this PSTI vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PSTI vs SCHDPSTI vs JEPIPSTI vs OPSTI vs KOPSTI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.